Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

ipal investigator in the study, commented, "There is a real need for novel therapies in PBC.  The clinically meaningful results from this study are highly supportive of OCA's potential as an effective new drug. We know now that OCA is effective given both in addition to UDCA and, from this study, when given alone.  The reductions in AP levels were very substantial and occurred within a month.  The effects on IgM and inflammatory markers suggest that OCA may have disease modifying properties."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved 20 centers in 7 countries and has given us and the PBC thought leaders involved a better understanding of the potent mechanism of action of OCA.  With the international PBC network we have established, we are well positioned to conduct a Phase III program.  We are currently discussing requirements for approval with FDA and have received guidance from the EMA supportive of our proposed program."

Mark Pruzanski, MD, Intercept's Chief Executive Officer, added, "The remarkable results achieved with OCA treatment in this study, together with the previously announced positive Phase II results with our drug added to UDCA in refractory PBC patients and in diabetic patients with nonalcoholic fatty liver disease, supports OCA's potential as a novel hepatoprotective drug that may help preserve liver function in patients with a variety of chronic liver diseases."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. Intercept has announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, and in type 2 diabetics with nonalcoholic fatty liver disease.  These clinical data and OCA's mechanism
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... WASHINGTON, Oct. 8 As Congress wraps up work ... of Transplantation,s (AST) Public Policy Committee arrived on Capitol ... health care provision that would ensure kidney transplant recipients ... The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients ...
... Adnavance Technologies Inc., a developer of direct detection ... Randy White, Ph.D. chief executive officer, will present initial ... clinical samples during company presentations at the following conferences: ... at 10:00 a.m. Eastern Time at the Walter E. ...
Cached Medicine Technology:AST on Capitol Hill to Promote Transplant Drug Extension Provision With Senate as Part of Health Care Reform 2Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 2
(Date:7/11/2014)... July 11, 2014 Utilizing the Keller ... Dr. William Koenig, has topped a record number of ... has performed over 400 successful procedures without the occurrence ... is well known across the country for his expertise ... record has long been the foundation for numerous studies ...
(Date:7/11/2014)... 2014 (HealthDay News) -- In people with sex addiction, ... to that seen in drug addicts as they consume ... differences in brain activity between patients who have compulsive ... of drug addicts," study author Dr. Valerie Voon, of ... university news release. Voon,s research involved 19 men ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- U.S. health officials have ... exposed to live anthrax during a safety mishap last ... and Prevention officials have announced a moratorium on the ... government labs. In a report issued Friday, the ... make sure a similar incident doesn,t occur again. Last ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... Israel, April 29 Elbit Imaging Ltd.,(the "Company") (Nasdaq: ... by,Aurora Fidelity Trust Company Ltd., the trustee for the ... the Company (the "Trustee" and the "Notes",respectively), that due ... accounting firms, Zohar, Zohar & Co., the controlling shareholder ...
... levels increasing even within normal range associated with dangers ... of thyrotropin within the normal range may increase the ... Norwegian study finds. , Thyrotropin, a hormone produced by ... acts on the thyroid gland to stimulate its growth ...
... and sanitation, a new report co-authored by an expert at ... be done. , A major survey in Kazakhstan found that, ... a large number of people reported suffering from illnesses like ... Development Goal is to halve the number of people without ...
... in German . , Leipzig. Unlike in ... Republic and Poland did not so far lead to massive ... there are other reasons for the presence of empty apartments, ... findings of a research project conducted by the Helmholtz Centre ...
... -- More than 6,000 internists (doctors of internal ... will meet in Washington, D.C., for Internal Medicine ... College of Physicians (ACP), from May 15 - ... , Internal Medicine 2008 is the largest continuing ...
... 5-Star overall winner to launch Partner Enablement ... Program; prepares for significant partner growth, ENGLEWOOD CLIFFS, ... and recovery service provider and recent Gold,5-Star overall winner ... Partner Enablement Program at Interop 2008 in Las Vegas, ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 2Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 3Health News:Pituitary Hormone May Boost Women's Heart Risk 2Health News:Safe water? Lessons from Kazakhstan 2Health News:Shrinkage and aging are Europe-wide challenges 2Health News:Shrinkage and aging are Europe-wide challenges 3Health News:Shrinkage and aging are Europe-wide challenges 4Health News:ACP hosts largest medical education meeting for general and subspecialty internists 2Health News:Intronis Technologies to Launch Partner Enablement Program at INTEROP 2008 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: